sal003
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jun 2, 2023 (NCT07278830)
Timeline
Mechanism of action
EIF2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07253584 | Phase 3 | Dec 19, 2023 | Jiao Tong University, Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| NCT07295418 | Phase 3 | Oct 23, 2023 | Government of China, Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| NCT07278830 | Phase 2 | Jun 2, 2023 | Government of China, Shenzhen Salubris Pharmaceuticals Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals Co., Ltd. | For profit | 3 | 3 | 2 | 2023 |
| Government of China | Government | 2 | 0 | 2 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1